Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?

Expert Rev Hematol. 2012 Oct;5(5):475-8. doi: 10.1586/ehm.12.43.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Apoptosis
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Checkpoint Kinase 1
  • Drug Therapy, Combination
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Proteasome Inhibitors / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinases / chemistry
  • Protein Kinases / metabolism
  • Pyrazines / therapeutic use

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Histone Deacetylase Inhibitors
  • Proteasome Inhibitors
  • Protein Kinase Inhibitors
  • Pyrazines
  • Bortezomib
  • Protein Kinases
  • Checkpoint Kinase 1
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3